Compare Charles River Laboratories Intl. Inc (CRL) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs S&P Global Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.31 (market cap $13.46B), while S&P Global Inc trades at $408.69 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 9× Charles River Laboratories Intl. Inc's market cap, and S&P Global Inc pays a 0.95% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SPGI | |
|---|---|---|
Market Cap | $13.46B | $120.48B |
Sector | Health | Financials |
52-Week High | $282.00 | $534.79 |
52-Week Low | $145.57 | $370.42 |
Enterprise Value | $16.30B | $131.97B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
S&P Global (SPGI) trades at $409.55, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $4.83, beating estimates, with revenue growth accelerating to $15.34B in 2025. Analyst consensus remains strongly bullish with 85.7% buy ratings and a $523.20 price target, representing 28% upside potential from current levels.
SPGI presents a compelling investment case with robust profitability (30.5% net margin) and strategic AI partnerships, though technical indicators suggest near-term pressure. The key risk involves maintaining premium valuations (P/E 24.9) amid economic uncertainty, while institutional confidence remains high with aggressive buyback programs supporting shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
